219 related articles for article (PubMed ID: 30532570)
1. Cost-effectiveness and budget impact of liraglutide in type 2 diabetes patients with elevated cardiovascular risk: a US-managed care perspective.
Shah D; Risebrough NA; Perdrizet J; Iyer NN; Gamble C; Dang-Tan T
Clinicoecon Outcomes Res; 2018; 10():791-803. PubMed ID: 30532570
[TBL] [Abstract][Full Text] [Related]
2. Cost-Utility of Liraglutide Plus Standard of Care Versus Standard of Care in People with Type 2 Diabetes and Cardiovascular Risk in Thailand.
Deerochanawong C; Krittayaphong R; Romano JGU; Rhee NA; Permsuwan U
Diabetes Ther; 2023 Mar; 14(3):531-552. PubMed ID: 36719606
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial.
Reifsnider OS; Kansal AR; Wanner C; Pfarr E; Koitka-Weber A; Brand SB; Stargardter M; Wang C; Kuti E; Ustyugova A
Am J Kidney Dis; 2022 Jun; 79(6):796-806. PubMed ID: 34752913
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes.
Guzauskas GF; Rind DM; Fazioli K; Chapman RH; Pearson SD; Hansen RN
J Manag Care Spec Pharm; 2021 Apr; 27(4):455-468. PubMed ID: 33769850
[No Abstract] [Full Text] [Related]
5. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China.
Ramos M; Men P; Wang X; Ustyugova A; Lamotte M
Cost Eff Resour Alloc; 2021 Aug; 19(1):46. PubMed ID: 34348729
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece.
Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsapas A; Kourlaba G; Papageorgiou G; Maniadakis N
Clin Drug Investig; 2018 May; 38(5):417-426. PubMed ID: 29349708
[TBL] [Abstract][Full Text] [Related]
8. Lifetime Cost-effectiveness of Oral Semaglutide Versus Dulaglutide and Liraglutide in Patients With Type 2 Diabetes Inadequately Controlled With Oral Antidiabetics.
Risebrough NA; Baker TM; Zhang L; Ali SN; Radin M; Dang-Tan T
Clin Ther; 2021 Nov; 43(11):1812-1826.e7. PubMed ID: 34728099
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of second-line empagliflozin versus liraglutide for type 2 diabetes in the United States.
Reifsnider OS; Pimple P; Brand S; Bergrath Washington E; Shetty S; Desai NR
Diabetes Obes Metab; 2022 Apr; 24(4):652-661. PubMed ID: 34910356
[TBL] [Abstract][Full Text] [Related]
10. The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease.
Ehlers LH; Lamotte M; Monteiro S; Sandgaard S; Holmgaard P; Frary EC; Ejskjaer N
Diabetes Ther; 2021 May; 12(5):1523-1534. PubMed ID: 33856655
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of liraglutide in type II diabetes: a systematic review.
Zueger PM; Schultz NM; Lee TA
Pharmacoeconomics; 2014 Nov; 32(11):1079-91. PubMed ID: 25052903
[TBL] [Abstract][Full Text] [Related]
12. Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.
Lee WC; Samyshkin Y; Langer J; Palmer JL
J Med Econ; 2012; 15 Suppl 2():28-37. PubMed ID: 22834986
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of empagliflozin in the UK in an EMPA-REG OUTCOME subgroup with type 2 diabetes and heart failure.
Reifsnider OS; Kansal AR; Franke J; Lee J; George JT; Brueckmann M; Kaspers S; Brand SB; Ustyugova A; Linden S; Stargardter M; Hau N
ESC Heart Fail; 2020 Dec; 7(6):3910-3918. PubMed ID: 32909680
[TBL] [Abstract][Full Text] [Related]
14. Cost Effectiveness of Dulaglutide Compared with Liraglutide and Glargine in Type 2 Diabetes Mellitus Patients in Colombia.
Lasalvia P; Baquero L; Otálora-Esteban M; Castañeda-Cardona C; Rosselli D
Value Health Reg Issues; 2017 Dec; 14():35-40. PubMed ID: 29254540
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of weight-management pharmacotherapies in Canada: a societal perspective.
Olivieri AV; Muratov S; Larsen S; Luckevich M; Chan K; Lamotte M; Lau DCW
Int J Obes (Lond); 2024 May; 48(5):683-693. PubMed ID: 38291203
[TBL] [Abstract][Full Text] [Related]
16. Long-term Cost-effectiveness of Two GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide.
Hunt B; Kragh N; McConnachie CC; Valentine WJ; Rossi MC; Montagnoli R
Clin Ther; 2017 Jul; 39(7):1347-1359. PubMed ID: 28625506
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland.
Soini E; Virtanen O; Väätäinen S; Briere JB; Bowrin K; Millier A
Adv Ther; 2020 Jul; 37(7):3348-3369. PubMed ID: 32519113
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of empagliflozin compared with liraglutide based on cardiovascular outcome trials in Type II diabetes.
Ramos M; Ustyugova A; Hau N; Lamotte M
J Comp Eff Res; 2020 Aug; 9(11):781-794. PubMed ID: 32573253
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
